Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is 10 mg of dapagliflozin and 100 mg of sitagliptin. The dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs to be adjusted, adjust it gradually.
Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 5/50/1000 mg extended-release tablets should take 2 tablets together once daily.
If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be 10 mg dapagliflozin, 100 mg sitagliptin, and the current dose of metformin hydrochloride or a therapeutically equivalent dose.
For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the same as the previous doses of each component.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from another antihyperglycemic agent. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions).
Special populations
Patients with renal impairment
As the efficacy and safety of this medicine depend on renal function and dosage adjustment according to renal function is required, it is recommended that renal function be assessed before treatment and periodically thereafter.
No dose adjustment is necessary for patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other symptoms that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If the estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is used in conjunction with dapagliflozin, sitagliptin, and metformin to help manage blood sugar levels in patients with type 2 diabetes. It is used for patients who are also following dietary and exercise regimens, and helps enhance the effectiveness of blood sugar control. This contributes to maintaining stable blood sugar levels and preventing complications associated with diabetes. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.
How to take
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is 10 mg of dapagliflozin and 100 mg of sitagliptin. The dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs to be adjusted, adjust it gradually.
Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 5/50/1000 mg extended-release tablets should take 2 tablets together once daily.
If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be 10 mg dapagliflozin, 100 mg sitagliptin, and the current dose of metformin hydrochloride or a therapeutically equivalent dose.
For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the same as the previous doses of each component.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from another antihyperglycemic agent. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions).
Special populations
Patients with renal impairment
As the efficacy and safety of this medicine depend on renal function and dosage adjustment according to renal function is required, it is recommended that renal function be assessed before treatment and periodically thereafter.
No dose adjustment is necessary for patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other symptoms that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If the estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months.
Precautions
This medication contains the ingredients sitagliptin, dapagliflozin, and metformin, which are used for diabetes treatment.
Sitagliptin can rarely cause severe allergic reactions, so if you experience symptoms such as skin rash, difficulty breathing, or swelling of the face or neck, you should immediately stop taking this medication and consult a doctor.
Additionally, serious side effects such as acute pancreatitis, which is inflammation of the pancreas, have been reported. Therefore, if you experience symptoms such as abdominal pain, vomiting, or nausea, you should visit a hospital immediately.
Dapagliflozin can reduce the body's fluid volume and lower blood pressure, so patients at risk for dehydration or hypotension should use it with caution. Patients with decreased kidney function should take it under regular monitoring.
Metformin can rarely cause lactic acidosis, which can be life-threatening, so if you experience unusual symptoms such as shortness of breath, muscle pain, fatigue, or abdominal pain, you should notify medical staff immediately.
This medication should not be administered to patients with severely impaired kidney function, acute heart disease, severe liver disease, or severe infections.
Also, if you are scheduled for surgery or will be undergoing tests that involve contrast agents, you should temporarily stop taking this medication and only resume after confirming that kidney function is normal post-surgery.
When used in combination with multiple medications for blood sugar control, there is a risk of hypoglycemia, so symptoms of hypoglycemia such as dizziness, cold sweats, and severe fatigue should be carefully monitored.
Genital infections or urinary tract infections may occur, so if related symptoms appear, immediate treatment is necessary, especially if there is a history of such infections.
It is important to regularly check kidney function and liver function while taking this medication, and consult medical staff immediately if abnormal symptoms arise.
Side effects
Severe hypersensitivity reactions
anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
vulvovaginitis
balanitis
genital infection
Show 102 moreCollapse
urinary tract infection
fungal infection
perineal necrosis
decreased fluid volume
thirst
diabetic ketoacidosis
dizziness
constipation
dry mouth
lumbago
dysuria
polyuria
nocturia
interstitial nephritis
vulvar pruritus
genital pruritus
increased hematocrit
decreased serum creatinine clearance
dyslipidemia
elevated serum creatinine
elevated blood urea
weight loss
rash
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
gastroesophageal reflux disease
upper abdominal pain
diverticulosis
intestinal perforation
chronic pancreatitis
hyperglycemia
paresthesia
cerebral infarction
nerve compression
sinusitis
diverticulitis
pelvic inflammatory disease
pneumonia
pulmonary tuberculosis
asthenia
pain
ligament sprain
road traffic accident
drug overdose
ankle fracture
hand fracture
ileal fracture
meniscus injury
thoracic spine fracture
tibial fracture
keratitis
chronic obstructive pulmonary disease
hemoptysis
cerebral hemorrhage
peripheral artery occlusion
angina pectoris
myocardial infarction
choledocholithiasis
cholangitis
alcoholic cirrhosis
depression
suicide attempt
gastric adenocarcinoma
food allergy
erythrocytosis
dyspepsia
nausea
diarrhea
vomiting
urinary retention
increased alanine aminotransferase
increased aspartate aminotransferase
decreased appetite
headache
nasopharyngitis
chest pain
hunger
vaginal discharge
pruritus
urticaria
cold sweat
arthralgia
musculoskeletal pain
limb pain
muscle weakness
myalgia
osteoarthritis
ligament strain
diabetic retinopathy
cough
dyspnea
orthostatic hypotension
palpitations
insomnia
fatty liver
gallbladder polyp
tinnitus
taste disturbance
erythema
rash
Not everyone experiences these, and they can vary from person to person.
Storage
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best stored at room temperature between 1°C and 30°C, avoiding extremely hot or cold places.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.